Silencing FOXP2 Reverses Vemurafenib Resistance in BRAFV600E Mutant Papillary Thyroid Cancer and Melanoma Cells

0
271
A vemurafenib-resistant BRAFV600E melanoma cell line was established by gradually increasing the drug concentration.
[Endocrine]
Full Article